Evaluating the Effect of Nutritional Supplementation on Growth of Short and Lean Adolescents Girls
Double Blind, Randomized , Placebo Controlled Study to Evaluate the Effect of Nutritional Supplementation on Growth of Short and Lean Adolescents Girls
Study design:
Double blind, randomized, placebo controlled study. Participants will be randomly assigned either to the intervention group or the placebo control group. Randomization for the two study groups will be made in a ratio of 1:1.
The primary objective of the study is to assess the effect of 6-12 months treatment with nutritional supplementation standardized formula, in short and lean female adolescents on weight Standard Deviation Score (SDS) and height SDS The Secondary Objectives of the study are to assess the effect of 6-12 months treatment with nutritional supplementation standardized formula, in short and lean female adolescents on BMI SDS, growth velocity, time to puberty, quality of life and self-esteem The study will continue for 6 months of intervention versus active placebo, with additional optional 6 months (an extension period), in which participants at both groups, the intervention and the placebo, will be offered to continue their participation in the study with the study supplement. All analyses of the effect's on primary and secondary outcome measurements will take into account the consumption rate of the study formula/placebo
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Contact
Study Contact
- Name: Moshe Phillip, Prof
- Phone Number: 972-3-9253747
- Email: mosheph@clalit.org.il
Study Contact Backup
- Name: Alona Hamou, Msc
- Phone Number: 972-3-9253778
- Email: alonah@clalit.org.il
Study Locations
-
-
-
Be'er Sheva', Israel
- Soroka Medical Center
-
Petach-Tikva, Israel, 49202
- Schneider Children's Medical Center
-
Rishon Letsiyon, Israel
- Assaf Harofe
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Girls aged ≥9 years old
- Prepubertal - Tanner stage 1. (gonadarche) Breast at Tanner stage 1)
- Height and weight ≤ 10th percentile for age and gender.
- Height-SDS ≥ -2.5 SDS
- BMI-SDS>-2 SDS
- Low proportion between weight and height
- Signing inform consent forms
Exclusion Criteria:
- Diagnosis of Growth Hormone (GH) Deficiency or treatment with GH
- Any known chronic disease or dysmorphic syndrome including: bone diseases, organic brain diseases, neurological disease, past or current malignancy, chronic cardiac, renal or pulmonary problems
- Any known gastrointestinal disease including malabsorption
- Any known organic reason for growth retardation
- Any chronic treatment with medication that might affect appetite, weight or growth (for example SSRI's).
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Nutritional supplementation standardized formula
Powder added to water, containing about 25% of recommended DRI for Calories, high protein (25% of calories) and multi vitamin and mineral (25%-100% of DRI for recommended daily allowance (RDA) or adequate intake )
|
Powder added to water, containing about 25% of recommended Daily Recommended Intake (DRI) for Calories, high protein (25% of calories) and multi vitamin and mineral (25%-100% of DRI for recommended daily allowance (RDA) or adequate intake )
|
|
Placebo Comparator: Placebo comparator
Low caloric formula (Powder added to water), without added vitamins and minerals.
|
Low caloric formula (Powder added to water), without added vitamins and minerals
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Weight SDS (standard deviation score)
Time Frame: At 12 months
|
Standard deviation score of patient's weight at 12 months
|
At 12 months
|
|
Height SDS (standard deviation score)
Time Frame: At 12 months
|
Standard deviation score of patient's height at 12 months
|
At 12 months
|
|
Weight SDS (standard deviation score)
Time Frame: At 6 months
|
Standard deviation score of patient's weight at 6 months
|
At 6 months
|
|
Height SDS (standard deviation score)
Time Frame: At 6 months
|
Standard deviation score of patient's height at 6 months
|
At 6 months
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
BMI SDS (standard deviation score)
Time Frame: At 12 months
|
Standard deviation score of patient's BMI at 12 months
|
At 12 months
|
|
BMI SDS (standard deviation score)
Time Frame: At 6 months
|
Standard deviation score of patient's BMI at 6 months
|
At 6 months
|
|
Growth velocity
Time Frame: At 12 months
|
Growth velocity measured as delta height divided by 12 months
|
At 12 months
|
|
Growth velocity
Time Frame: At 6 months
|
Growth velocity measured as delta height divided by 6 months
|
At 6 months
|
|
Quality of life Questionnaire
Time Frame: At 12 months
|
Quality of life measured by quality of life questionnaire
|
At 12 months
|
|
Quality of life Questionnaire
Time Frame: At 6 months
|
Quality of life measured by quality of life questionnaire
|
At 6 months
|
|
Self-esteem Questionnaire
Time Frame: At 12 months
|
At 12 months
|
|
|
Self-esteem Questionnaire
Time Frame: At 6 months
|
At 6 months
|
Other Outcome Measures
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Physical Activity Questionnaire
Time Frame: At 12 months
|
At 12 months
|
|
|
Study Participation Questionnaire
Time Frame: At 6 months
|
At 6 months
|
|
|
Study Participation Questionnaire
Time Frame: At 12 months
|
At 12 months
|
|
|
Family Eating and Activity Habits Questionnaire
Time Frame: At 6 months
|
At 6 months
|
|
|
Family Eating and Activity Habits Questionnaire
Time Frame: At 12 months
|
At 12 months
|
|
|
Time to puberty initiation
Time Frame: At 12 months
|
Duration of time until breast at tanner stage >=2
|
At 12 months
|
|
Sleep Assessment Questionnaire
Time Frame: At 6 months
|
At 6 months
|
|
|
Sleep Assessment Questionnaire
Time Frame: At 12 months
|
At 12 months
|
|
|
Physical Activity Questionnaire
Time Frame: At 6 months
|
At 6 months
|
|
|
Parents Stands Towards Healty Lifestyle Questionnaire
Time Frame: At 12 months
|
At 12 months
|
|
|
Parents Stands Towards Healty Lifestyle Questionnaire
Time Frame: At 6 months
|
At 6 months
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Moshe Phillip, Prof, Schneider Children's Medical Center
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimated)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
Other Study ID Numbers
- rmc000214ctil
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.